Header Logo

Connection

CANDELARIA GOMEZ-MANZANO to Animals

Back to Details
This is a "connection" page, showing publications CANDELARIA GOMEZ-MANZANO has written about Animals.
CANDELARIA GOMEZ-MANZANO
Connection Strength
0.601
Animals
  1. The emerging field of viroimmunotherapy for pediatric brain tumors. Neuro Oncol. 2024 Nov 04; 26(11):1981-1993.
    View in: PubMed
    Score: 0.042
  2. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res. 2019 11 15; 25(22):6801-6814.
    View in: PubMed
    Score: 0.029
  3. Linking inflammation and cancer: the unexpected SYK world. Neuro Oncol. 2018 04 09; 20(5):582-583.
    View in: PubMed
    Score: 0.027
  4. TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation. Mol Cell Biol. 2017 Nov 01; 37(21).
    View in: PubMed
    Score: 0.026
  5. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget. 2016 Mar 29; 7(13):16146-57.
    View in: PubMed
    Score: 0.023
  6. Macrophage Ablation Reduces M2-Like Populations and Jeopardizes Tumor Growth in a MAFIA-Based Glioma Model. Neoplasia. 2015 Apr; 17(4):374-84.
    View in: PubMed
    Score: 0.022
  7. Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol. 2014 Aug; 16(8):1025-6.
    View in: PubMed
    Score: 0.021
  8. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014 Apr 30; 5(8):2208-20.
    View in: PubMed
    Score: 0.020
  9. Gene therapy. Handb Clin Neurol. 2012; 104:331-8.
    View in: PubMed
    Score: 0.017
  10. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget. 2010 Dec; 1(8):700-709.
    View in: PubMed
    Score: 0.016
  11. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des. 2009; 15(4):353-64.
    View in: PubMed
    Score: 0.014
  12. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008 Dec; 10(6):940-5.
    View in: PubMed
    Score: 0.014
  13. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol. 2008 06; 23(6):773-80.
    View in: PubMed
    Score: 0.013
  14. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther. 2008 May; 7(5):794-6.
    View in: PubMed
    Score: 0.013
  15. E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett. 2008 May 18; 263(2):157-63.
    View in: PubMed
    Score: 0.013
  16. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia. 2006 May; 8(5):419-28.
    View in: PubMed
    Score: 0.012
  17. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res. 2006 Jan 15; 12(2):556-62.
    View in: PubMed
    Score: 0.011
  18. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst. 2005 Nov 02; 97(21):1589-600.
    View in: PubMed
    Score: 0.011
  19. Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses. 2024 Nov 14; 16(11).
    View in: PubMed
    Score: 0.011
  20. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro Oncol. 2024 08 05; 26(8):1509-1525.
    View in: PubMed
    Score: 0.010
  21. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene. 2004 Mar 11; 23(10):1821-8.
    View in: PubMed
    Score: 0.010
  22. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther. 2024 Mar 06; 32(3):722-733.
    View in: PubMed
    Score: 0.010
  23. Development of a rabbit human glioblastoma model for testing of endovascular selective intra-arterial infusion (ESIA) of novel stem cell-based therapeutics. Neuro Oncol. 2024 01 05; 26(1):127-136.
    View in: PubMed
    Score: 0.010
  24. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity. Cancer Res Commun. 2023 06; 3(6):1118-1131.
    View in: PubMed
    Score: 0.010
  25. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 07; 10(7).
    View in: PubMed
    Score: 0.009
  26. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight. 2022 04 08; 7(7).
    View in: PubMed
    Score: 0.009
  27. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. Mol Cancer Ther. 2022 03 01; 21(3):471-480.
    View in: PubMed
    Score: 0.009
  28. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol. 2021 11 02; 23(11):1911-1921.
    View in: PubMed
    Score: 0.009
  29. Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma. J Neurosurg. 2022 Mar 01; 136(3):757-767.
    View in: PubMed
    Score: 0.008
  30. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.008
  31. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.008
  32. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Clin Cancer Res. 2021 03 15; 27(6):1807-1820.
    View in: PubMed
    Score: 0.008
  33. Endovascular Selective Intra-Arterial Infusion of Mesenchymal Stem Cells Loaded With Delta-24 in a Canine Model. Neurosurgery. 2020 12 15; 88(1):E102-E113.
    View in: PubMed
    Score: 0.008
  34. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019 05 28; 10(1):2235.
    View in: PubMed
    Score: 0.007
  35. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. Acta Neuropathol Commun. 2019 04 29; 7(1):64.
    View in: PubMed
    Score: 0.007
  36. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res. 2017 07 15; 77(14):3894-3907.
    View in: PubMed
    Score: 0.006
  37. Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens. PLoS One. 2016; 11(4):e0153814.
    View in: PubMed
    Score: 0.006
  38. Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. Neuro Oncol. 2016 08; 18(8):1109-19.
    View in: PubMed
    Score: 0.006
  39. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.
    View in: PubMed
    Score: 0.006
  40. Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol. 2015 Aug; 13:33-9.
    View in: PubMed
    Score: 0.005
  41. The oncolytic adenovirus ?24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity. J Bone Miner Res. 2014 Oct; 29(10):2287-96.
    View in: PubMed
    Score: 0.005
  42. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014; 9(5):e97407.
    View in: PubMed
    Score: 0.005
  43. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
    View in: PubMed
    Score: 0.004
  44. Targeting brain tumor stem cells with oncolytic adenoviruses. Methods Mol Biol. 2012; 797:111-25.
    View in: PubMed
    Score: 0.004
  45. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer. 2011 Aug 17; 11:358.
    View in: PubMed
    Score: 0.004
  46. RB-E2F1: molecular rheostat for autophagy and apoptosis. Autophagy. 2010 Nov; 6(8):1216-7.
    View in: PubMed
    Score: 0.004
  47. Advances in translational research in neuro-oncology. Arch Neurol. 2011 Mar; 68(3):303-8.
    View in: PubMed
    Score: 0.004
  48. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther. 2010 Apr; 17(4):289-97.
    View in: PubMed
    Score: 0.004
  49. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther. 2009 Mar; 16(3):256-65.
    View in: PubMed
    Score: 0.003
  50. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther. 2008 Mar; 16(3):487-93.
    View in: PubMed
    Score: 0.003
  51. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007 Dec 15; 67(24):11499-504.
    View in: PubMed
    Score: 0.003
  52. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007 Sep 19; 99(18):1410-4.
    View in: PubMed
    Score: 0.003
  53. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res. 2007 Sep 01; 67(17):8255-63.
    View in: PubMed
    Score: 0.003
  54. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther. 2007 Aug; 14(8):756-61.
    View in: PubMed
    Score: 0.003
  55. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res. 2007 May 01; 67(9):4005-9.
    View in: PubMed
    Score: 0.003
  56. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia. 2005 Jan; 7(1):48-56.
    View in: PubMed
    Score: 0.003
  57. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003 May 07; 95(9):652-60.
    View in: PubMed
    Score: 0.002
  58. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci. 2003 May 01; 8:d577-88.
    View in: PubMed
    Score: 0.002
  59. Delivery of cell cycle genes to block astrocytoma growth. J Neurooncol. 2001 Feb; 51(3):277-87.
    View in: PubMed
    Score: 0.002
  60. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000 Jan 06; 19(1):2-12.
    View in: PubMed
    Score: 0.002
  61. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 1999 Feb 15; 59(4):895-900.
    View in: PubMed
    Score: 0.002
  62. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med. 1998 Jun; 4(6):685-90.
    View in: PubMed
    Score: 0.002
  63. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology. 1998 May; 50(5):1307-15.
    View in: PubMed
    Score: 0.002
  64. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene. 1997 Oct 23; 15(17):2049-57.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.